CDXC ChromaDex Corporation Stock Quote

CDXC [NASD]

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	1.30%	Shs Outstand	67.99M	Perf Week	-17.39%
Market Cap	430.46M	Forward P/E	-	EPS next Y	-0.11	Insider Trans	-4.58%	Shs Float	45.68M	Perf Month	-20.20%
Income	-23.30M	PEG	-	EPS next Q	-0.09	Inst Own	30.40%	Short Float	8.22%	Perf Quarter	-36.74%
Sales	62.00M	P/S	6.94	EPS this Y	42.10%	Inst Trans	-6.70%	Short Ratio	6.75	Perf Half Y	-45.23%
Book/sh	0.62	P/B	10.19	EPS next Y	68.60%	ROA	-44.20%	Target Price	-	Perf Year	39.82%
Cash/sh	0.57	P/C	11.09	EPS next 5Y	-	ROE	-76.30%	52W Range	3.82 - 23.66	Perf YTD	31.67%
Dividend	-	P/FCF	-	EPS past 5Y	-33.40%	ROI	-	52W High	-73.29%	Beta	1.64
Dividend %	-	Quick Ratio	2.80	Sales past 5Y	21.90%	Gross Margin	61.20%	52W Low	65.45%	ATR	0.50
Employees	110	Current Ratio	3.60	Sales Q/Q	15.70%	Oper. Margin	-37.40%	RSI (14)	20.81	Volatility	13.35% 6.40%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-34.40%	Profit Margin	-37.50%	Rel Volume	2.29	Prev Close	6.67
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 03 AMC	Payout	-	Avg Volume	556.26K	Price	6.32
Recom	1.60	SMA20	-20.06%	SMA50	-26.07%	SMA200	-21.18%	Volume	1,255,442	Change	-5.25%

Oct-16-19

Initiated

Oppenheimer

Outperform

Feb-14-19

Initiated

B. Riley FBR

Buy

Nov-27-17

Resumed

H.C. Wainwright

Buy

$6 → $8

Sep-25-17

Initiated

Ladenburg Thalmann

Buy

Jan-03-17

Initiated

Rodman & Renshaw

Buy

Sep-15-21 04:16PM	Why ChromaDex Stock Is Sinking Today Motley Fool
08:37AM	Why Are ChromaDex Shares Trading Lower On Wednesday? Benzinga
06:30AM	ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judges Ruling in Patent Infringement Lawsuit Business Wire
Sep-09-21 06:33AM	Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now? Simply Wall St.
Aug-10-21 01:22AM	Investors in ChromaDex (NASDAQ:CDXC) have made a solid return of 118% over the past five years Simply Wall St.
Aug-03-21 10:31PM	ChromaDex Corporation (CDXC) Q2 2021 Earnings Call Transcript Motley Fool
05:25PM	ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:02PM	ChromaDex Corporation Reports Second Quarter 2021 Financial Results Business Wire
Jul-27-21 03:02PM	Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out for Zacks -9.35%
Jul-20-21 06:33AM	ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021 Business Wire
Jul-11-21 04:11AM	ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 27% Above Its Share Price Simply Wall St.
Jun-16-21 10:35AM	CHROMADEX'S HEALTHY AGING PRODUCTS GAIN NEW TRACTION WITH THREE HUGE DISTRIBUTION AGREEMENTS INCLUDING WALMART Benzinga
06:33AM	ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP) Business Wire
Jun-11-21 01:38AM	This Is The Reason Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Might Be Underpaid Simply Wall St.
Jun-08-21 10:40AM	ChromaDex launches Tru Niagen® in Walmart Stores; Shares Pop 7% SmarterAnalyst +14.81%
Jun-07-21 12:19PM	Why ChromaDex Stock Is Jumping Today Motley Fool
09:42AM	ChromaDex Shares Jump on Tru Niagen's Launch In Walmart Stores Benzinga
06:57AM	ChromaDex to Sell Tru Niagen Healthy-Aging Product in Walmart TheStreet.com
06:44AM	ChromaDex stock jumps after its Tru Niagen to become available at Walmart MarketWatch
06:33AM	ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States Business Wire
Jun-02-21 02:50AM	Is ChromaDex Corporation's (NASDAQ:CDXC) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
May-07-21 04:30PM	ChromaDex Corporation (CDXC) Q1 2021 Earnings Call Transcript Motley Fool -12.24%
May-06-21 06:20PM	ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:02PM	ChromaDex Corporation Reports First Quarter 2021 Financial Results Business Wire
02:45PM	Chromadex Corp. to Host Earnings Call ACCESSWIRE
May-04-21 06:33AM	ChromaDex and Ro Partner for New Product Development Business Wire
May-03-21 06:33AM	ChromaDex to Present at Benzingas Global Small Cap Conference on May 13, 2021 Business Wire
02:01AM	ChromaDex Corporation (NASDAQ:CDXC): Are Analysts Optimistic? Simply Wall St.
Apr-29-21 06:33AM	ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 Business Wire
Apr-28-21 06:33AM	ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen® Business Wire +6.25%
Apr-19-21 06:33AM	ChromaDex Appoints Fadi Karam as Chief Marketing Officer Business Wire
Mar-31-21 06:33AM	ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency Business Wire +6.14%
Mar-28-21 04:18AM	Is Now An Opportune Moment To Examine ChromaDex Corporation (NASDAQ:CDXC)? Simply Wall St.
Mar-24-21 06:33AM	ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference Business Wire -11.91%
Mar-22-21 08:42AM	Is the Options Market Predicting a Spike in ChromaDex (CDXC) Stock? Zacks -12.73%
Mar-18-21 06:33AM	ChromaDex to Present at the Zooming with LD Virtual Investor Conference Business Wire -6.33%
Mar-16-21 06:48PM	Why ChromaDex Trounced the Market on Tuesday Motley Fool +9.97%
Mar-11-21 12:00AM	ChromaDex Corporation (CDXC) Q4 2020 Earnings Call Transcript Motley Fool +5.21%
Mar-10-21 05:35PM	ChromaDex (CDXC) Reports Q4 Loss, Tops Revenue Estimates Zacks -6.20%
04:20PM	Recap: ChromaDex Q4 Earnings Benzinga
04:02PM	ChromaDex Corporation Reports 2020 Financial Results Business Wire
03:24PM	Why ChromaDex Stock Blasted Almost 30% Higher Today Before Falling Into the Red Motley Fool
01:30PM	Chromadex Corp. to Host Earnings Call ACCESSWIRE
06:34AM	ChromaDex Announces Retail Distribution of Tru Niagen® in Walmart Stores Across the United States Business Wire
Mar-09-21 06:32AM	ChromaDex to Present at Oppenheimer 31st Annual Healthcare Conference Business Wire +9.67%
Mar-08-21 09:00AM	ChromaDex (CDXC) Surges 12%: Is This an Indication of Further Gains? Zacks
06:31AM	ChromaDex Appoints Preventative Medicine Specialist Dr. David L. Katz to its Scientific Advisory Board Business Wire
Mar-03-21 12:30PM	ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks -8.06%
Feb-24-21 06:30AM	New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients Business Wire
Feb-22-21 06:30AM	ChromaDex Announces $25 Million Private Placement of Common Stock Business Wire +15.64%
Feb-20-21 02:17AM	Is ChromaDex's (NASDAQ:CDXC) Share Price Gain Of 110% Well Earned? Simply Wall St.
Feb-19-21 06:35AM	ChromaDex to Report Fourth Quarter 2020 Financial Results on Wednesday, March 10, 2021 Business Wire +10.51%
Feb-12-21 01:13PM	This Bioscience Company Is Trying To Defy The Aging Process Benzinga -10.43%
Feb-04-21 06:35AM	New Study Results Finds Nutritional Protocol Including Nicotinamide Riboside Reduces Liver Fat and Improves Liver Function Business Wire
Dec-22-20 12:28AM	What You Need To Know About ChromaDex Corporation's (NASDAQ:CDXC) Investor Composition Simply Wall St.
Dec-14-20 08:32AM	ChromaDex (CDXC) in Focus: Stock Moves 5.6% Higher Zacks -6.91%
Dec-02-20 03:49PM	Is ChromaDex (CDXC) A Good Stock To Buy Now? Insider Monkey
06:35AM	ChromaDex to Present at Benzingas Inaugural Small Cap Conference in December 2020 Business Wire
Nov-17-20 06:35AM	ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU) Business Wire
Nov-09-20 06:32AM	ChromaDex and Watsons Launch New TRU NIAGEN® EX Stick Packs in Hong Kong, Expanding Product Line and Advancing Global Retail Partnership Business Wire +7.13%
Nov-07-20 08:32AM	Have Insiders Been Buying ChromaDex Corporation (NASDAQ:CDXC) Shares? Simply Wall St.
08:16AM	Earnings Update: Here's Why Analysts Just Lifted Their ChromaDex Corporation (NASDAQ:CDXC) Price Target To US$8.00 Simply Wall St.
Nov-04-20 11:32PM	ChromaDex Corporation (CDXC) Q3 2020 Earnings Call Transcript Motley Fool
05:55PM	ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM	ChromaDex Corporation Reports Third Quarter 2020 Financial Results Business Wire
02:30PM	Chromadex Corp. to Host Earnings Call ACCESSWIRE
Nov-03-20 10:09AM	Preview: ChromaDex's Earnings Benzinga +6.08%
Oct-28-20 06:35AM	ChromaDex to Report Third Quarter 2020 Financial Results on Wednesday, November 4, 2020 Business Wire
Oct-27-20 10:22AM	Oppenheimer: These 3 Stocks Are Poised to Surge by at Least 60% TipRanks
Oct-19-20 06:32AM	New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice Business Wire
Oct-14-20 09:10AM	Celltrient Cellular Energy Products Featuring Tru Niagen® Launch in US Business Wire
Oct-08-20 06:32AM	New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function Business Wire -6.35%
Oct-07-20 04:30AM	ChromaDex Pops 28% On Anti-Ageing Supplement Covid-19 Study SmarterAnalyst
Oct-06-20 06:35AM	ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30% Business Wire +27.52%
Sep-09-20 06:33AM	New Preclinical Study Finds Niagen® Prevents Light-Induced Retinal Damage in Mice Business Wire
Sep-01-20 04:34PM	LD Micro: 360 Companies--Set to Present this Week. ACCESSWIRE
Aug-26-20 06:32AM	ChromaDex to Present at the LD 500 Virtual Investor Conference Business Wire
Aug-18-20 06:32AM	New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients Business Wire
Aug-06-20 07:10PM	ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	ChromaDex Corporation Reports Second Quarter 2020 Financial Results Business Wire
Aug-05-20 09:00AM	LD Micro - Announces Preliminary List of Presenters for the LD-500 ACCESSWIRE
Jul-30-20 12:33PM	Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-28-20 06:32AM	ChromaDex to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020 Business Wire
Jul-16-20 06:33AM	New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism Business Wire
Jul-14-20 06:32AM	ChromaDex External Research Program (CERP) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) Research Business Wire
Jul-09-20 06:36AM	ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model Business Wire
Jul-07-20 06:34AM	ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models Business Wire
Jun-30-20 06:32AM	New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage Business Wire
Jun-17-20 06:33AM	ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation Business Wire
Jun-16-20 06:32AM	ChromaDex to Present at June 2020 Lytham Partners Virtual Investor Growth Conference Business Wire
02:09AM	ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Nicotinamide Riboside (NR) PR Newswire
Jun-15-20 09:42PM	Edited Transcript of CDXC.OQ earnings conference call or presentation 11-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-03-20 06:33AM	First-of-Its-Kind Human Tissue Study Finds Link Between NAD Decline and Alcohol-Related Liver Disease (ArLD) Business Wire
Jun-01-20 06:32AM	ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting Business Wire
May-27-20 03:15PM	Here is What Hedge Funds Think About ChromaDex Corporation (CDXC) Insider Monkey
06:32AM	ChromaDex to Participate in Panel on Master Files for Dietary Supplements Hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN) Business Wire
May-21-20 06:32AM	ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition Business Wire
May-12-20 01:01AM	ChromaDex Corporation (CDXC) Q1 2020 Earnings Call Transcript Motley Fool -5.49%
May-11-20 05:25PM	ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM	ChromaDex Corporation Reports First Quarter 2020 Financial Results Business Wire

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fried Robert N	CEO	May 13	Buy	6.65	10,000	66,500	63,001	May 17 08:30 AM
BLOCK STEPHEN A	Director	Mar 16	Option Exercise	2.60	20,000	52,100	36,667	Mar 17 06:41 PM
BLOCK STEPHEN A	Director	Mar 16	Sale	13.17	20,000	263,400	16,667	Mar 17 06:41 PM
BLOCK STEPHEN A	Director	Mar 15	Option Exercise	1.92	32,500	62,400	49,167	Mar 17 06:41 PM
BLOCK STEPHEN A	Director	Mar 15	Sale	11.15	32,500	362,375	16,667	Mar 17 06:41 PM
Jaksch Frank L Jr	EXECUTIVE CHAIRMAN OF BOARD	Dec 10	Option Exercise	4.62	41,667	192,502	262,168	Dec 11 05:06 PM
Jaksch Frank L Jr	EXECUTIVE CHAIRMAN OF BOARD	Dec 10	Sale	5.19	37,829	196,333	224,339	Dec 11 05:06 PM
FARR KEVIN M	CHIEF FINANCIAL OFFICER	Nov 06	Buy	4.43	5,000	22,150	41,625	Nov 06 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience